FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma
“While the potential applications for SRF231 in oncology are quite broad, we are particularly excited about the opportunity to provide benefit to patients with multiple myeloma. We have already demonstrated the ability of our antibody to increase phagocytosis of myeloma cells and to shrink tumors in preclinical models,” said
SRF231 is currently being evaluated in a multi-center, open-label Phase I trial to assess safety and tolerability in multiple ascending doses with the goal of establishing a recommended dose for further study. Following the dose escalation phase, the company intends to evaluate the safety and efficacy of SRF231 in a targeted set of solid and hematologic malignancies.
SRF231 is a fully human monoclonal antibody therapeutic targeting CD47, a protein overexpressed on many cancer cells which prevents them from being engulfed and eliminated by macrophage mediated phagocytosis. SRF231 preclinical results presented at the 2016
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com.
Source: Surface Oncology, Inc.